The present disclosure relates to a method of treating Tuberous Sclerosis Complex (TSC). The present disclosure further provides an isolated polynucleotide molecule comprising, a polynucleotide comprising an AAV9 vector a polynucleotide encoding a TSC1 or a TSC2, or variant thereof and a promoter. The present disclosure further provides a pharmaceutical composition comprising an isolated polynucleotide molecule.
